![Tan Kambia](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Mr. Tan Kambia is a Director of Public Equity at Invus SAS. He is responsible for trading (flow, IPO and blocs), as well as representing Invus in dealing with brokers, sell side sales and syndicates.
Prior to joining Invus in 2014, he worked for Bank of America Merrill Lynch for 17 years in Trading and Sales Trading.
He is a graduate of EM Strasbourg Business School majoring in Finance.
He also spent a year at Trinity College in Dublin as a student in Economics.
Aktive Positionen von Tan Kambia
| Unternehmen | Position | Beginn |
|---|---|---|
Invus SAS (Investment Management)
 Invus SAS (Investment Management) Investment ManagersFinance Invus-IM takes significant, long-term positions in public companies whose fundamentals and management they believe in. They focus on stocks that are trading below the firm's assessment of their intrinsic business value. The average holding period in their public equity portfolio is not measured in weeks or months but years. Leveraging their deep expertise in the healthcare sector, Invus-IM also works with their private equity team jointly investing in Series A and Series B rounds of private biotech companies making transformational bets on the future of healthcare, where they continue to support them as they go public. | Trading-Equity | 01.01.2014 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
2
Beziehungen ersten Grades
1
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
Invus SAS (Investment Management)
Invus SAS (Investment Management) Investment ManagersFinance Invus-IM takes significant, long-term positions in public companies whose fundamentals and management they believe in. They focus on stocks that are trading below the firm's assessment of their intrinsic business value. The average holding period in their public equity portfolio is not measured in weeks or months but years. Leveraging their deep expertise in the healthcare sector, Invus-IM also works with their private equity team jointly investing in Series A and Series B rounds of private biotech companies making transformational bets on the future of healthcare, where they continue to support them as they go public. | Finance |
